Hurun India Rich List 2026 edition · 1 director
- #326 Sujit Jaysukh Bhayani & family ₹11,600 Cr
Market Cap
₹11,332 Cr
SUDEEPPHRM · NSE
Share Price
₹1,003.30
+0.26% today
Revenue
₹642 Cr
FY 2025-26 · +27.9% YoY
EBITDA
₹223 Cr
Margin 34.7%
Net Profit
₹173 Cr
FY 2025-26 · +24.3% YoY
P/E (TTM)
61.9x
P/B 12.8x
ROE
25.4%
ROCE 27.9%
Debt / Equity
0.21
Interest cover 4.1x
About Sudeep Pharma Limited
Data last updated:
Sudeep Pharma Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 21 December 1989 and has been in existence for over 37 years.
Its director Sujit Jaysukh Bhayani and family are #326 on the Hurun India Rich List 2026.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1989PLC013141. Its GSTIN is 24AACCS9716J1Z4 (Gujarat). The company holds 2 GST registrations, all of them active. Its shares are listed on BSE: 544619 and NSE: SUDEEPPHRM.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.29 Cr. It is led by directors including Sujit Jaysukh Bhayani (Managing Director) and Shanil Sujit Bhayani (Whole-Time Director).
Its last annual general meeting (AGM) was held on 04 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 129/1/A G.I.D.C. Estate Nandesari, Vadodara, Gujarat, India – 391340.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹642.26 Cr, a growth of 27.9% compared to the previous year. For the same year it recorded a net profit of ₹172.92 Cr (net margin 26.9%) and EBITDA of ₹222.8 Cr (EBITDA margin 34.7%). The net worth stands at ₹883.33 Cr (up 79.1% YoY). Total assets are valued at ₹1,078.31 Cr (up 70.5% YoY).
The company has about 377 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Sudeep Pharma and Sudeep Pharma. As per MCA filings, the company has open charges of ₹271.5 Cr and satisfied charges of ₹81.9 Cr on record. Court records list 19 cases involving the company, including 5 filed by the company and 14 filed against it. The company has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025. Its 10 peer companies in the Healthcare industry (Preventive Healthcare Supplements) are compared by revenue, 5 larger and 5 smaller; the largest is Bright Lifecare Private Limited with revenue of ₹1,368.3 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2021, listing 424 overdue payments to 124 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudeepgroup.com.
Company Details of Sudeep Pharma Limited
CIN L24231GJ1989PLC013141
Registration Number 013141
Incorporation Date 21 December 1989
ROC Ahmedabad
Listing Status Listed (BSE: 544619, NSE: SUDEEPPHRM)
Company Status Active
Date of Last AGM 04 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN History of Sudeep Pharma Limited
Sudeep Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ1989PLC013141, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1989PLC013141 | Current |
| U24231GJ1989PLC013141 | Previous |
| U24231GJ1989PTC013141 | Previous |
Key People
Sujit Jaysukh Bhayani Managing Director Shanil Sujit Bhayani Whole-Time Director Ajay Shrirang Kandelkar Whole-Time Director Recognitions & Rankings of Sudeep Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address129/1/A G.I.D.C. Estate Nandesari, Vadodara, Gujarat, India – 391340
- IndustryHealthcare, Preventive Health Supplements
Comprehensive company report
Sudeep Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Sudeep Pharma Limited
Sudeep Pharma operates two associated brands: Sudeep Pharma and Sudeep Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical excipients and ingredients are manufactured for multiple industries. | sudeeppharma.com | |
| Sudeep Pharma is involved in pharmaceutical and nutrition sectors. | sudeepgroup.com |
Business Activity of Sudeep Pharma Limited
The main business activity of Sudeep Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Sudeep Pharma Limited FY 2025-26 filings available
Sudeep Pharma Limited reported revenue of ₹642.26 Cr (up 27.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹642 Cr
+27.9% YoY
EBITDA
₹223 Cr
+16.6% YoY
Profit After Tax
₹173 Cr
+24.3% YoY
Net Worth
₹883 Cr
+79.1% YoY
Total Assets
₹1,078 Cr
+70.5% YoY
Total Debt
₹150 Cr
+9.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Balance sheet | |||||||
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Net worth | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Cash & bank | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Cash flow | |||||||
| Cash from operations | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Cash from investing | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Cash from financing | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Balance sheet | ||||||
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Net worth | 786 | 430 | 335 | 237 | 168 | 116 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Cash & bank | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Cash flow | ||||||
| Cash from operations | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Cash from investing | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Cash from financing | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| Other income | 28.59 | 9.33 | 6.10 | 9.52 | 7.39 | 3.44 | 3.22 |
| Total expenses | 419 | 311 | 277 | 339 | 276 | 171 | 97.63 |
| Employee cost | 51.89 | 38.34 | 29.41 | 66.10 | 15.55 | 11.46 | 9.34 |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Depreciation | 14.81 | 10.59 | 9.01 | 7.92 | 4.53 | 3.53 | 3.07 |
| Interest | 8.50 | 6.90 | 4.74 | 5.78 | 1.72 | 0.97 | 0.93 |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Tax | 53.79 | 44.12 | 41.63 | 23.66 | 18.43 | 9.68 | 6.56 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 872 | 481 | 355 | 222 | 162 | 113 | 79.54 |
| Shareholders' funds (net worth) | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Minority interest | 14.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 148 | 135 | 75.03 | 82.26 | 83.69 | 31.06 | 17.09 |
| Unsecured loans | 2.13 | 2.30 | 3.05 | 0.83 | 0.00 | 0.00 | 3.08 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Total liabilities | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Assets | |||||||
| Gross block | 378 | 216 | 197 | 166 | 157 | 83.31 | 71.80 |
| Net block | 337 | 189 | 180 | 158 | 137 | 67.65 | 59.58 |
| Capital work in progress | 185 | 88.22 | 44.66 | 25.97 | 8.13 | 24.00 | 8.16 |
| Investments | 0.00 | 0.14 | 0.13 | 3.03 | 0.00 | 19.10 | 6.00 |
| Inventories | 216 | 129 | 66.58 | 71.00 | 36.54 | 17.47 | 9.50 |
| Sundry debtors | 228 | 185 | 145 | 93.71 | 107 | 55.18 | 30.32 |
| Cash & bank balances | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Loans & advances | 65.73 | 58.15 | 50.11 | 51.98 | 31.68 | 14.89 | 12.39 |
| Total current assets | 624 | 424 | 275 | 227 | 197 | 99.50 | 56.31 |
| Total current liabilities | 87.17 | 78.41 | 72.58 | 108 | 91.53 | 62.83 | 24.27 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 36.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 | 4.25 |
| Net cash from operating activities | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Net cash from investing activities | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Net cash from financing activities | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Net change in cash | (10.07) | 22.83 | 3.67 | (11.17) | 9.52 | 7.86 | (0.16) |
| Closing cash | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA growth | +16.6% | +4.7% | +102.4% | +33.6% | +53.1% | +73.7% | - |
| PBT growth | +24.7% | +4.6% | +103.3% | +25.3% | +59.5% | +74.9% | +9997.0% |
| Net income growth | +24.3% | +4.3% | +113.9% | +24.6% | +50.5% | +84.4% | - |
| Revenue CAGR (3Y) | +14.4% | +13.5% | +28.8% | +51.6% | - | - | - |
| EBITDA CAGR (3Y) | +35.2% | +41.5% | +60.6% | +52.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.1% | +27.6% | +29.0% | +14.5% | +14.6% | +15.5% | +14.7% |
| Return on capital employed | +27.9% | +35.5% | +48.4% | +33.1% | +35.7% | +35.4% | +25.0% |
| Return on net worth | +25.4% | +32.8% | +46.0% | +32.2% | +36.2% | +34.2% | +22.3% |
| Debt / equity | 0.21 | 0.25 | 0.28 | 0.43 | 0.41 | 0.26 | 0.25 |
| Long-term debt / equity | 0.06 | 0.06 | 0.06 | 0.13 | 0.15 | 0.11 | 0.10 |
| Interest cover | 4.09 | 3.82 | 2.73 | 7.03 | 2.73 | 2.39 | 4.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.16 | 2.43 | 2.53 | 2.65 | 2.86 | 2.77 | 1.71 |
| Inventory turnover | 3.73 | 5.14 | 6.68 | 7.97 | 12.70 | 15.95 | 12.95 |
| Debtors turnover | 3.11 | 3.04 | 3.85 | 4.27 | 4.23 | 5.03 | 4.06 |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 78.21 | 50.48 | 252.69 | 158.47 | 1,159.15 | 810.48 | 574.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| Other income | 38.50 | 8.38 | 8.20 | 11.18 | 8.08 | 3.67 |
| Total expenses | 218 | 224 | 211 | 315 | 277 | 172 |
| Employee cost | 28.95 | 26.06 | 20.22 | 60.79 | 13.55 | 11.46 |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Depreciation | 7.11 | 6.12 | 5.15 | 4.83 | 4.19 | 3.53 |
| Interest | 6.73 | 5.68 | 3.68 | 4.83 | 1.63 | 0.97 |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Tax | 37.51 | 33.66 | 34.23 | 23.60 | 18.10 | 9.97 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 775 | 418 | 333 | 235 | 167 | 115 |
| Shareholders' funds (net worth) | 786 | 430 | 335 | 237 | 168 | 116 |
| Secured loans | 125 | 119 | 58.05 | 69.69 | 72.66 | 31.06 |
| Unsecured loans | 1.72 | 1.78 | 2.43 | 0.83 | 0.00 | 0.00 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Total liabilities | 913 | 552 | 396 | 308 | 242 | 148 |
| Assets | ||||||
| Gross block | 124 | 120 | 106 | 94.64 | 139 | 83.31 |
| Net block | 102 | 105 | 95.89 | 89.82 | 120 | 67.65 |
| Capital work in progress | 161 | 87.71 | 43.50 | 25.59 | 4.38 | 23.21 |
| Investments | 32.07 | 31.51 | 28.75 | 18.70 | 15.11 | 24.21 |
| Inventories | 131 | 64.60 | 45.42 | 52.40 | 26.33 | 15.10 |
| Sundry debtors | 80.13 | 162 | 141 | 126 | 123 | 58.14 |
| Cash & bank balances | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Loans & advances | 157 | 40.70 | 35.40 | 47.81 | 27.71 | 14.86 |
| Total current assets | 458 | 313 | 231 | 233 | 192 | 96.29 |
| Total current liabilities | 53.75 | 48.20 | 50.96 | 105 | 86.61 | 61.92 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 30.35 | 8.59 | 6.35 | 14.87 | 8.19 | 4.10 |
| Net cash from operating activities | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Net cash from investing activities | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Net cash from financing activities | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Net change in cash | (28.16) | 21.75 | 2.24 | (8.52) | 6.68 | 4.09 |
| Closing cash | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA growth | -9.3% | -0.1% | +48.9% | +31.0% | +48.8% | - |
| PBT growth | +12.1% | -2.2% | +45.7% | +28.9% | +56.6% | +9997.0% |
| Net income growth | +12.4% | -2.4% | +45.9% | +29.2% | +48.9% | - |
| Revenue CAGR (3Y) | -5.7% | +1.1% | +16.4% | - | - | - |
| EBITDA CAGR (3Y) | +10.5% | +24.9% | +42.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +31.8% | +26.8% | +28.5% | +16.6% | +15.2% | +16.1% |
| Return on capital employed | +20.7% | +28.5% | +38.7% | +34.8% | +37.0% | +36.7% |
| Return on net worth | +17.7% | +25.1% | +34.3% | +33.2% | +36.8% | +35.5% |
| Debt / equity | 0.20 | 0.24 | 0.23 | 0.35 | 0.36 | 0.26 |
| Long-term debt / equity | 0.06 | 0.06 | 0.03 | 0.07 | 0.11 | 0.11 |
| Interest cover | 5.94 | 4.48 | 2.88 | 5.72 | 2.55 | 2.30 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 2.77 | 3.16 | 3.43 | 3.46 | 3.11 | 2.81 |
| Inventory turnover | 3.47 | 6.48 | 7.03 | 10.26 | 16.65 | 17.71 |
| Debtors turnover | 2.79 | 2.35 | 2.57 | 3.24 | 3.81 | 4.93 |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 69.59 | 44.01 | 2,374.56 | 1,681.07 | 1,193.96 | 822.76 |
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sudeep Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board of Directors of Sudeep Pharma Limited
Sudeep Pharma has 8 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
Showing 6 of 8 current directors. View all directors
Peer Comparison of Sudeep Pharma Limited
Sudeep Pharma Limited is compared with the companies closest to it by revenue in the Healthcare industry (Preventive Healthcare Supplements). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bright Lifecare Private Limited | ₹1,368.3 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | New Delhi, Delhi, India |
| Vestige Marketing Private Limited | ₹1,153.64 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | New Delhi, Delhi, India |
| DSM Nutritional Products India Private Limited | ₹1,132.96 Cr (FY 2025) | •••• | •••• | 18.0% | •••• | Mumbai, Maharashtra, India |
| Venkateshwara B.V. Biocorp Private Limited | ₹917.66 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Pune, Maharashtra, India |
| Sudeep Pharma Limited this company | ₹642.26 Cr (FY 2026) | •••• | •••• | 27.9% | •••• | Vadodara, Gujarat, India |
| Maxcure Nutravedics Limited | ₹600.9 Cr (FY 2025) | •••• | •••• | -18.0% | •••• | Delhi, India |
| Glanbia Performance Nutrition (India) Private Limited | ₹487.19 Cr (FY 2025) | •••• | •••• | 21.0% | •••• | Gurgaon, Haryana, India |
| Chhattisgarh Agro Food Corporation Limited | ₹479.23 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Raipur, Chhattisgarh, India |
| KCL Limited | ₹466.31 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | New Delhi, Delhi, India |
| Tirupati Wellness Private Limited | ₹414.79 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Sirmaur, Himachal Pradesh, India |
| Sumtinath Trading Private Limited | ₹388.44 Cr (FY 2022) | •••• | •••• | 500.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Sudeep Pharma by revenue in the Healthcare industry (Preventive Healthcare Supplements), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Charges & Borrowings of Sudeep Pharma Limited
Open charges
₹271.5 Cr
Satisfied charges
₹81.9 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jul 2026 | The Hongkong and Shanghai Banking Corporation Limited | ₹125 Cr | Open |
| 30 Dec 2024 | Others | ₹75 Cr | Open |
| 29 Sep 2020 | Citi Bank N.A. | ₹20 Cr | Open |
| 20 Aug 2019 | Citi Bank N.A. | ₹6.5 Cr | Open |
| 27 Jan 2014 | Citi Bank N.A. | ₹45 Cr | Open |
Total charge records: 18 View all charges
Deals & Funding of Sudeep Pharma Limited
Sudeep Pharma Limited has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025.
Total deals
11
Secondary share transfers
6
Funding rounds
2
Market trades
2
IPO
1
Disclosed funding
₹170 Cr
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2025 | Market trade | ₹447.7 Cr | Buyer: Junomoneta Finsol Private Limited , Goldmine Stocks Pvt Ltd, Irage Broking Services LLP Seller: Junomoneta Finsol Private Limited , Irage Broking Services LLP , Goldmine Stocks Pvt Ltd |
| Nov 2025 | Market trade | ₹64.11 Cr | Buyer: Irage Broking Services LLP Seller: Irage Broking Services LLP |
| Nov 2025 | IPO | ₹895 Cr | Investors: Sbi Life Insurance Company Limited , Shamyak Investment Private Limited , Tata Aia Life Insurance Company Limited Seller: Sujeet Jaysukh Bhayani HUF, 3 individuals |
| May 2025 | Funding round | ₹160 Cr | Investors: Ashok India Equity Investment Trust Plc, Whiteoak Capital Opportunities Fund, Dalmia Family Office Trust |
| Jan 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Premium access
Full deal history
All 11 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Sudeep Pharma Limited
Sudeep Pharma Limited has 19 court cases on record: 5 filed by Sudeep Pharma, 14 filed against it. All cases are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Total cases
19
Filed by the company
5
Filed against the company
14
Disposed
19
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 15 | 12 | 0 |
| High courts | 4 | 2 | 0 |
Cases on record (5 of 19)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Gujarat | Court case (COMP) | Filed against the company by Penta Freight Private Limited | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Government of Gujarat | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Income - Tax Department | Disposed |
| District court, Vadodara, Gujarat | Civil suit | Filed against the company by an individual | Disposed |
| District court, Vadodara, Gujarat | Civil suit | Filed against the company by an individual | Disposed |
Premium access
Full case history
All 19 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Sudeep Pharma Limited
Sudeep Pharma Limited has 4 MSME Form 1 returns on record between 2019 and 2021, listing 424 overdue payments to 124 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 124)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Saita Screens & Filters | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Thermolab Scientific Equipments Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 4 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Sudeep Pharma Limited
Employment history and EPFO contributions of people linked to Sudeep Pharma.
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sudeep Pharma Limited
Sudeep Pharma Limited has 25 board changes on record since 1995: 9 appointments and 16 cessations. The latest: Milin Kaimas Mehta was appointed as Director on 26 Jun 2026.
AGM
Sudeep Pharma Limited last Annual general meeting of members was held on 04 Aug 2026 as per latest MCA records.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 125.00 Cr with Charge ID 101352762 was registered on 13 Jul 2026.
Appointed
Milin Kaimas Mehta was appointed as Director.
Filing
Sudeep Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others of Rs. 75.00 Cr registered on 30 Dec 2024 with Charge ID 101026268 was modified on 17 Sep 2025.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101026268 was registered on 30 Dec 2024.
Charges
A charge registered on 29 Jan 2022 via Charge ID 100539717 with Others was fully satisfied on 12 Dec 2024.
Ceased
Raghunandan Sathyanarayan Rao ceased to be Additional Director.
Ceased
Reshma Suresh Patel ceased to be Additional Director.
Ceased
Samaresh Parida ceased to be Additional Director.
Ceased
Sujit Gulati ceased to be Additional Director.
Appointed
Ajay Shrirang Kandelkar was appointed as Whole-Time Director.
56 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Sudeep Pharma Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sudeep Pharma Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sudeep Pharma Limited
Sudeep Pharma has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AACCS9716J1Z4 | Gujarat | Active | 01 Jul 2017 |
| 03AACCS9716J1Z8 | Punjab | Active | 09 Jan 2024 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sudeep Pharma Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Sudeep Pharma Limited
Frequently Asked Questions about Sudeep Pharma Limited
Sudeep Pharma is an active public limited company based in Vadodara, Gujarat, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 21 December 1989 (37+ years old) and is registered under CIN L24231GJ1989PLC013141. Listed on BSE: 544619 and NSE: SUDEEPPHRM.
Sudeep Pharma reported revenue of ₹642.26 Cr for FY 2025-26 (up 27.9% YoY) based on consolidated financials.
Sudeep Pharma has 8 current directors:
- Sujit Jaysukh Bhayani - Managing Director
- Shanil Sujit Bhayani - Whole-Time Director
- Ajay Shrirang Kandelkar - Whole-Time Director
- Samaresh Parida - Director
- Raghunandan Sathyanarayan Rao - Director
- Sujit Gulati - Director
- Reshma Suresh Patel - Director
- Milin Kaimas Mehta - Director
The GSTIN of Sudeep Pharma is 24AACCS9716J1Z4, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 03AACCS9716J1Z8 (Punjab).
The CIN (Corporate Identification Number) of Sudeep Pharma is L24231GJ1989PLC013141. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sudeep Pharma is listed on both BSE (code: 544619) and NSE (symbol: SUDEEPPHRM).
Sudeep Pharma has 19 court cases on record: 5 filed by the company and 14 filed against it. Most are in the district courts.
Sudeep Pharma was incorporated on 21 December 1989, making it 37+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Sudeep Pharma has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025.
The peers of Sudeep Pharma by revenue are Bright Lifecare Private Limited, Vestige Marketing Private Limited, DSM Nutritional Products India Private Limited, Venkateshwara B.V. Biocorp Private Limited, Maxcure Nutravedics Limited and 5 more, all in the Healthcare industry (Preventive Healthcare Supplements).
Milin Kaimas Mehta was appointed as Director on 26 Jun 2026. Raghunandan Sathyanarayan Rao ceased to be Additional Director on 25 Oct 2024. Reshma Suresh Patel ceased to be Additional Director on 25 Oct 2024. Sudeep Pharma has 25 board changes on record in total.
Sudeep Pharma has 4 MSME Form 1 returns on record between 2019 and 2021, listing 424 overdue payments to 124 micro and small suppliers. The latest return was filed on 28 Oct 2021.